PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1954671
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1954671
The global steam and hydrogen peroxide biological indicators market was valued at USD 803.76 million in 2025 and is projected to grow to USD 865.02 million in 2026, reaching USD 1,644.03 million by 2034, exhibiting a CAGR of 8.36% from 2026 to 2034. North America led the global market in 2025 with a 34.90% share, driven by stringent infection control regulations, growing surgical volumes, and rapid adoption of sterilization monitoring protocols across healthcare and pharmaceutical sectors. The U.S. market is expected to reach USD 387.7 million by 2030, owing to rising surgical site infections and increased focus on sterilization in hospitals and dental clinics.
Market Overview and Product Insights
Biological indicators (BIs) provide a direct measure of sterilization effectiveness, ensuring reliable monitoring in processes using steam, hydrogen peroxide, ethylene oxide, and other sterilizing agents. The increasing emphasis on sterilization in healthcare facilities, pharmaceutical, biotechnology, and food industries drives market growth. Regulatory standards enforcing contamination prevention, combined with new product launches, have further accelerated the adoption of steam and hydrogen peroxide biological indicators.
Among product types, self-contained vials (SCBIs) hold the largest share due to their high reliability, ease of use, and rapid results. In 2026, the self-contained vials segment accounted for 67.33% of the market, valued at USD 582.4 million, driven by higher adoption in both developed and emerging healthcare markets. Spore strips hold the second-largest share due to their lower cost and suitability for smaller clinics and healthcare facilities. Spore-suspension indicators are also used but represent a smaller market segment.
Application Insights
By application, healthcare facilities dominate, accounting for 72.26% of the global market in 2026, valued at USD 625.1 million. The rise in hospital-acquired infections (HAIs) and the growing number of surgical procedures necessitate routine sterilization monitoring. Pharmaceutical and medical device companies hold the second-largest share, as stringent sterilization requirements prevent contamination and product recalls, emphasizing the importance of biological indicators in production workflows.
COVID-19 Impact
The COVID-19 pandemic accelerated demand for sterilization and disinfectant monitoring products. Hospitals, dental clinics, and pharmaceutical companies increased sterilization measures to avoid viral or bacterial HAIs. For example, 3M's medical solutions division reported a 25.9% revenue increase in 2020, reflecting the heightened demand for BIs during the pandemic. While post-pandemic growth normalized, the long-term demand remains strong due to ongoing surgical procedures and heightened infection control protocols.
Market Trends
The market is witnessing a shift toward rapid biological indicators, offering faster results than conventional products. Traditional indicators require 72-168 hours for incubation, whereas rapid BIs provide results in minutes. Regulatory approvals, such as the U.S. FDA approval of the Sterrad Velocity Biological Indicator in January 2020, support this trend, increasing adoption across pharmaceutical and medical device manufacturing.
Market Growth Factors
Rising surgical volumes, increasing prevalence of chronic diseases, and higher healthcare expenditure drive the need for sterile medical instruments. Globally, approximately 313 million surgeries are performed annually, according to the WHO. This creates significant demand for monitoring devices, including steam and hydrogen peroxide biological indicators. Product innovations, such as STERIS Spordex SCBI Ampoules launched in December 2020, further enhance market growth.
Restraining Factors
The adoption of BIs faces competition from alternate solutions like enzyme indicators, which offer faster results, ease of use, and lower costs. The high cost of BIs also limits widespread adoption, particularly in developing regions. For instance, the FDA approved Instant 20s Enzymatic Indicator by True Indicating LLC in December 2021, capable of monitoring steam sterilization processes rapidly, challenging traditional BIs.
North America led in 2025 with USD 280.9 million, and the U.S. market is projected at USD 287.5 million by 2026. Europe shows steady growth, with the UK reaching USD 33.4 million and Germany USD 53.8 million by 2026, driven by geriatric populations and longer hospital stays. Asia Pacific is expected to witness the highest CAGR due to rapid expansion of pharmaceutical and medical device manufacturing, with Japan at USD 55.6 million, China at USD 72.3 million, and India at USD 41.8 million by 2026. Latin America and the Middle East & Africa account for smaller shares due to lower awareness.
Key Players and Industry Developments
Major players include 3M, STERIS, ASP, Getinge, Mesa Labs, Tuttnauer, Bioquell, and Terragene. Notable developments include:
Conclusion
The steam and hydrogen peroxide biological indicators market is set for robust growth, expanding from USD 803.76 million in 2025 to USD 1,644.03 million by 2034, driven by increasing surgical procedures, stringent sterilization regulations, and technological innovations in rapid biological indicators. Despite challenges from alternate products and high costs, the ongoing focus on patient safety, HAIs prevention, and sterilization efficiency ensures strong market potential across healthcare and pharmaceutical sectors globally.
Segmentation By Product Type, By Application, and By Geography
By Product Type * Self-contained Vials
By Application * Pharmaceutical & Medical Device Companies
By Geography
North America (By Product Type, By Application, and By Country)